People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Tripling the dosage of the Wegovy weight-loss drug leads to more weight loss, Novo Nordisk said Friday. The Danish drugmaker ...

GLP-1 drugs used for weight loss involve all kinds of side effects—good and not-so-good—that may or may not strike the ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...

Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final ...

Argus lowered the firm’s price target on Novo Nordisk (NVO) to $110 from $140 but keeps a Buy rating on the shares and contends that the ...

The latest buzz around the popular weight loss drugs Ozempic, Mounjaro and Wegovy is to reduce the doseage to avoid the ...

Heavy drinkers who were ­taking weight-loss jabs in a Dublin clinic significantly reduced their ­alcohol intake down from 12 ...

In previous First Word columns, I discussed the effects of SGLT2 inhibitors on the kidney to prevent progression of chronic ...

Those in the jab trials, however, kept off between 10 and 25 per cent of their body weight over the same timeframe, depending ...